ArticleLeukemia2024
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
Open access · hybridAbstract readLetter
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- HSCT and CAR-T: a power couple-but who serves whom?Frontiers in immunology · 2026Review
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Targeting CD19 CAR-T With MND Promoter Enhances Tumour Killing.Journal of cellular and molecular medicine · 2025Article
- Recent advances in universal chimeric antigen receptor T cell therapy.Journal of hematology & oncology · 2025Review
- Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.Bone marrow transplantation · 2025Review
- Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.Blood cancer journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 2 countries.
Wenyi LuDepartment of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China.ORCID 0000-0002-3975-6636
Hairong LyuDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Xia XiaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Xue BaiDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Meng ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Jiaxi WangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Yedi PuDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Juanxia MengDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Xiaomei ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Haibo ZhuDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Ting YuanDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Bing WangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Xin JinDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Xinping CaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Zhao WangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Tianle XieDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Haotian MengDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Alexey V StepanovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0003-1616-4408
Alexander G GabibovM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.
Yuxin AnDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Rui SunDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Yu ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Mikhail A MaschanDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.ORCID 0000-0003-1735-0093
Zunmin Zhu *Department of Hematology, Institute of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, China. zhuzm1964@163.com.
Hongkai Zhang *State Key Laboratory of Medicinal Chemical Biology and College of Life Science, Nankai University, Tianjin, China. hongkai@nankai.edu.cn.ORCID 0000-0003-2186-5508
Mingfeng Zhao *Department of Hematology, Tianjin First Central Hospital, Tianjin, China. mingfengzhao@sina.com.ORCID 0000-0002-5995-7558
Nankai University · CNInstitute of Bioorganic Chemistry · RUDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology · RUZhengzhou University · CN
Funding
National Natural Science Foundation of China (National Science Foundation of China) 81800105National Natural Science Foundation of China (National Science Foundation of China) 81970180National Natural Science Foundation of China (National Science Foundation of China) 82261138553Tianjin Science and Technology Committee (Tianjin Municipal Science and Technology Commission) 20YFZCSY00800Tianjin Science and Technology Committee (Tianjin Municipal Science and Technology Commission) 21JCZDJC01240Tianjin Science and Technology Committee (Tianjin Municipal Science and Technology Commission) 22JCQNJC00820Tianjin Science and Technology Committee (Tianjin Municipal Science and Technology Commission) TJYXZDXK-056B
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antigens, CD19Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveTissue DonorsTransplantation, HomologousAdolescentAdultFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenRecurrenceYoung AdultAntigens, CD19Receptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.